San Diego, CA (PRWEB) -- On June 14, 2012, the attorneys at Blumenthal, Nordrehaug & Bhowmik filed a brief opposing the Metropolitan Water District's motion to dismiss a lawsuit alleging that the Metropolitan Water District of Southern California is distributing a drug through the public water systems despite the fact that the drug has not been approved by the FDA to fluoridate drinking water to fight tooth decay.
Foli v. Metropolitan Water District is currently pending in the Federal District Court for the Southern District of California as Case No. 11CV1765 JLS (BLM).
According to the opposition filed by the California attorneys at Blumenthal, Nordrehaug & Bhowmik, "Defendants' use of unapproved HydroFluoSilicic Acid ("HFSA") for the treatment of disease is arbitrary and capricious." Specifically, the lawsuit seeks to stop the Water District's alleged practice of "injecting hydrofluosilicic acid into the water supply for the purpose of treating disease and dental cavities" on the basis that "Hydrofluosilicic acid has never been approved by the United States Food and Drug Administration for the treatment of disease or dental cavities."
The attorneys argue in the opposition that the Water District's use of a drug not approved by the FDA to medicate Plaintiffs and other people in order to forcibly treat disease without their consent allegedly violates the Constitutional rights of these citizens.